In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of patients with major depressive disorder (MDD). Published in Cell Reports, the research demonstrates that music can synchronize neural circuits in the brain, leading to significant antidepressant effects where conventional therapies have failed. This discovery not only highlights the potential of music therapy but also paves the way for new, non-invasive treatments that could revolutionize mental health care. As the medical community continues to explore alternative therapies for MDD, attention is turning to innovative companies like Alzamend Neuro, Inc. (NASDAQ:ALZN), Neurocrine Biosciences, Inc. (NASDAQ:NBIX), Takeda Pharmaceutical Company Limited (NYSE:TAK), Axsome Therapeutics, Inc. (NASDAQ:AXSM) and Biogen Inc. (NASDAQ:BIIB).

Alzamend Neuro, Inc. (NASDAQ:ALZN) is dedicated to rapidly developing and bringing to market safe and effective treatments for psychiatric illnesses, which affect over 600 million people in the world. The company’s pipeline features two key drug candidates: AL001 and ALZN002. AL001, a patented ionic cocrystal technology, is designed to safely deliver lithium for treating Alzheimer’s, bipolar disorder, MDD, and PTSD, while minimizing the harmful side effects of traditional lithium therapy. ALZN002 employs a patented approach to restore the immune system’s ability to combat Alzheimer’s disease.

On August 12, Alzamend Neuro announced it has partnered with Massachusetts General Hospital to conduct a Phase II clinical study of AL001 for treating major depressive disorder (MDD). The study will be led by Dr. Ovidiu Andronesi, Associate Professor of Radiology at Harvard University.

AL001 aims to offer a new lithium-based treatment for MDD. While lithium is a well-established treatment for bipolar disorder, its use in MDD is often off-label. Alzamend‘s study will compare the brain’s lithium levels using AL001 against traditional lithium salts to determine the minimum effective dose with improved safety.

Alzamend recently completed a Phase IIA trial identifying a maximum tolerated dose of AL001. This new formulation may avoid the need for regular therapeutic drug monitoring, a requirement with current lithium treatments due to their narrow therapeutic window and potential toxicity. The study’s findings will be pivotal for AL001’s potential approval through the FDA’s Section 505(b)(2) pathway, which allows for new formulations of approved drugs. Alzamend is optimistic about AL001’s potential to meet regulatory standards and offer a safer, more effective lithium-based treatment for MDD.

“We are elated to partner with Massachusetts General Hospital and Dr. Andronesi in this pivotal study for our lead therapeutic candidate AL001,” said Stephan Jackman, Chief Executive Officer of Alzamend. “If we can develop a next-generation lithium product (AL001) with an improved safety profile and enhanced biodistribution in the brain that would not routinely require TDM, it would constitute a major improvement over current lithium-based treatments and positively impact the 21+ million Americans afflicted with MDD. We look forward to providing more details regarding the study’s timeline and market opportunity in the near future.”

Last week, Alzamend Neuro announced a collaboration with Massachusetts General Hospital (MGH) to conduct a Phase II clinical trial for AL001 as a potential treatment for Alzheimer’s disease and Bipolar Disorder. This trial will include patients and healthy subjects to compare the bioavailability and brain distribution of AL001 with that of a currently marketed lithium carbonate product. Led by Dr. Ovidiu Andronesi of Harvard University, the trial aims to establish the safe, effective, and tolerable dosing requirements for AL001.

Click here for more information about Alzamend Neuro, Inc. (NASDAQ:ALZN).

Breakthroughs in Depression Treatments from Biopharmaceutical Companies

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has made significant progress in the treatment of major depressive disorder (MDD) with its drug candidate, Ingrezza. Initially approved for treating tardive dyskinesia, Ingrezza is now showing promise in clinical trials for depression. The company recently reported positive results from a Phase 2 study, demonstrating its potential effectiveness in reducing depressive symptoms in patients with MDD. This success has positioned Neurocrine as a strong contender in the field of depression treatment, offering hope for patients who have not responded to traditional therapies.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) is pioneering new approaches to treating depression, particularly with its drug AXS-05. This novel oral treatment, which modulates multiple neurotransmitter systems, has shown rapid and sustained antidepressant effects in clinical trials. Axsome‘s unique multi-modal mechanism offers a promising alternative for patients with treatment-resistant MDD, and the company is poised to make a significant impact on the future of depression treatment.

Takeda Pharmaceutical Company Limited (NYSE:TAK) is advancing its role in the mental health field with its antidepressant, Trintellix (vortioxetine). Trintellix is already approved for treating MDD and is distinguished by its unique mechanism of action that enhances serotonin activity in the brain. Takeda continues to explore additional applications for Trintellix and other potential treatments, reinforcing its position in the competitive landscape of depression therapy. The company remains committed to addressing the unmet needs in mental health through innovative research and development.

Biogen Inc. (NASDAQ:BIIB), in collaboration with Sage Therapeutics, has faced setbacks with its experimental depression treatment, zuranolone (brand name Zurzuvae). Although zuranolone initially generated excitement as a potential fast-acting treatment for MDD, recent trial failures have dampened expectations. A major study did not meet its primary endpoint, raising concerns about the drug’s efficacy and future prospects. This outcome highlights the challenges in developing new treatments for depression, and Biogen’s next steps in this area remain uncertain.

As of July 18, Alzamend Neuro, Inc. (NASDAQ:ALZN) completed two tranches of a private placement under a $25 million purchase agreement.

Click here for more information about Alzamend Neuro, Inc. (NASDAQ:ALZN).

Featured Image @ Freepik

Disclaimer

1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2) The Article was issued on behalf of and sponsored by, Alzamend Neuro, Inc. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-alzn.

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.’s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.

6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management’s expectations regarding Alzamend Neuro, Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Alzamend Neuro, Inc.’s industry; (b) market opportunity; (c) Alzamend Neuro, Inc.’s business plans and strategies; (d) services that Alzamend Neuro, Inc. intends to offer; (e) Alzamend Neuro, Inc.’s milestone projections and targets; (f) Alzamend Neuro, Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Alzamend Neuro, Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Alzamend Neuro, Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Alzamend Neuro, Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Alzamend Neuro, Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Alzamend Neuro, Inc.’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Alzamend Neuro, Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Alzamend Neuro, Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Alzamend Neuro, Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Alzamend Neuro, Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Alzamend Neuro, Inc.’s business operations (e) Alzamend Neuro, Inc. may be unable to implement its growth strategy; and (f) increased competition.

Except as required by law, Alzamend Neuro, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Alzamend Neuro, Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Alzamend Neuro, Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.

7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Alzamend Neuro, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Alzamend Neuro, Inc. or such entities and are not necessarily indicative of future performance of Alzamend Neuro, Inc. or such entities.

8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on pressreach.com constitutes advice or a recommendation.

• Featured News RSS feed
• Investing News RSS feed
• Daily Press Releases RSS feed
• Trading Tips RSS feed
• Investing Videos RSS feed

Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube